VIVUS — Q2 2012 Earnings Presentation
41 slides from VIVUS's earnings presentation, Aug 10, 2012
Slide 1: Vivus: A Pharmaceutical Company
Vivus ® A Pharmaceutical Company
Slide 2: Agenda
Agenda Leland Wilson, CEO General Update Manufacturing Timothy Morris, SVP and CFO Q2 Results Intellectual Property Barbara Troupin MD, VP Qsymia REMS and Label Mike Miller, SVP and CCO US Launch of Qsymia 3
Slide 3: Company Update: Two FDA Approvals
Company Update Two FDA Approvals Qsymia™ Approved by FDA on July 17, 2012 Presently manufacturing launch quantities at Catalent Launch in Q4 2012 Executed CSO agreement with PDI CHMP oral hearing scheduled September 2012 STENDRA™ Approved by FDA on April 29, 2012 Partnering discussions underway MTPC
Slide 4: Qsymia Supply Chain in Place
Qsymia Supply Chain in Place API Supplier: ScinoPharm Leading API manufacturer with >1000 DMF Registrations Manufacturing topiramate API Excellent FDA track record since 2007 Manufacturer: Catalent Pharma Solutions 75 years of pharmaceutical experience 30 facilities in 5 continents Distributor: Card
Slide 5: Commercial Manufacturing Prepared for Launch
Commercial Manufacturing Prepared for Launch Catalent Pharma Solutions – Headquarters in Somerset, NJ Catalent has a proven track record Manufactures many of the most Rx’d drugs Supplied Qsymia since beginning of Phase 3 clinical trials Capacity sufficient to meet commercial demand Manufacturing of
Slide 6: MTPC Amendment Executed
MTPC Amendment Executed August 7, 2012 Transfers manufacturing rights to VIVUS Adds an additional six months to the timing requirements for a major market launch Expands field of use for avanafil in all indications 7
Slide 7: Q2 Results & IP
Q2 Results & IP Timothy E. Morris Senior Vice President and CFO 8
Slide 8: Second Quarter 2012 Financial Update
Second Quarter 2012 Financial Update Cash and investment balance 6/30/2012: $310 million Q2 Net Loss: $24 million First half 2012 cash used in operations: $37 million Headcount (FTE and FT consultants) July 31: 107 9
Slide 9: Planned Investor Relations Events
Planned Investor Relations Events UBS Biotech Summer Conference, San Francisco Stifel Nicolaus Healthcare Conference 2012, Boston Citi Biotech Day, Boston BioCentury NewsMakers in the Biotech Industry, New York Morgan Stanley Global Healthcare Conference, New York Rodman & Renshaw Global Investment
Slide 10: Qsymia Protected by Issued Patents
Qsymia Protected by Issued Patents VIVUS has issued patents that protect Qsymia into 2020 4 issued US Patents, 166 claims EP patent-validated in 19 countries Patents in Canada and Australia Pending patents in the US, Europe, Asia and elsewhere should provide additional protection, if granted Market
Slide 11: Strong Patent Position
Strong Patent Position Validity The Shank and McElroy references were considered by the USPTO during prosecution The presumption is that the issued claims are valid in view of these references The burden is high for a 3rd party to challenge validity based on references the PTO already considered Fre
Slide 12: Qsymia REMS and Package Insert
Qsymia REMS and Package Insert Barbara Troupin, MD, MBA Vice President, Scientific Communication and Risk Management 13
Slide 13: Qsymia Risk Evaluation and Mitigation Strategy
Qsymia Risk Evaluation and Mitigation Strategy Goal Inform prescribers and female patients of childbearing potential about the risk, the importance of pregnancy prevention and the need to minimize fetal exposure Components Medication Guide (patient focused labeling) Elements to Assure Safe Use (ETAS
Slide 14: REMS ETASU – Certified Pharmacies
REMS ETASU – Certified Pharmacies Certified Home Delivery Pharmacy Network Qsymia will only be distributed to Certified Home Delivery Pharmacies for launch Unable to resell or distribute Qsymia outside of the certified pharmacy network Must dispense Med Guide and patient brochure with every prescrip
Slide 15: What Elements are not in the Qsymia REMS?
What Elements are not in the Qsymia REMS? It does not have a patient registry It does not require any type of patient enrollment There are not “hard stops” for the ability to prescribe and dispense Pregnancy tests are recommended and not required; so no pharmacy lockout and no stipulations on prescr
Slide 16: Qsymia Approved Indication
Qsymia Approved Indication For use as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with BMI of 30 (obese) or 27 or greater (overweight) with at least one weight related co-morbidity such as hypertension, type 2 diabetes, or dyslipidemia
Slide 17: Tolerability and Safety
Tolerability and Safety Warnings and precautions include increased risk of orofacial clefts in infants exposed in first trimester of pregnancy, increase in resting heart rate, mood changes including depression, cognitive impairment, acute angle glaucoma, and metabolic acidosis Most common side effec
Slide 18: Dosing and Administration
Dosing and Administration Once daily in the morning with or without food Start with Qsymia 3.75 mg/23 mg - 14 days Increase to Qsymia 7.5 mg/46 mg – 12 weeks <3% weight loss, discontinue or escalate the dose To escalate: Increase to Qsymia 11.25 mg/69 - 14 days Qsymia 15 mg/92 mg – 12 weeks <5% weig
Slide 19: Two Simple Ways to Rx Qsymia for Patients
Two Simple Ways to Rx Qsymia for Patients 1. HCP can complete the Qsymia Rx form and fax to the patient’s home delivery pharmacy of choice 2. HCP hands Rx to patient and patient calls pharmacy of choice for fulfillment The Qsymia Certified Home Delivery Pharmacy Network (with contact information and
Slide 20: Qsymia US Launch Plan
Qsymia US Launch Plan Michael P. Miller Senior Vice President and Chief Commercial Officer 22
Slide 21: Obesity is Headline News
Obesity is Headline News 23 *Number of stories in major news and business publications from January through June 2012 Source: Dow Jones Factiva “ American May Be Fatter Than We Think, Study Says” –TIME 4/03/12 “ Doctors should screen patients for obesity” –Reuters 6/26/12 “ Rates of Obesity and Seve
Slide 22: Qsymia Interest
Qsymia Interest Very significant media coverage of approval Almost 500,000,000 impressions based on print, online, broadcast and social media since approval Qsymia website “live” at approval In July, over 91,000 unique visitors to www.Qsymia.com Almost 13,000 have registered for more information on
Slide 23: Qsymia – Key Messages
Qsymia – Key Messages First pharmacotherapy with the proven potential of allowing patients to achieve and maintain >10% weight loss For completers in pivotal studies, categorical weight loss after one year of tx was 64% at >10%, and 43% at >15% with top dose Shown to be well tolerated in clinical tr
Slide 24: Pivotal 1-Year Studies: Co-Primary Endpoints
Pivotal 1-Year Studies: Co-Primary Endpoints (ITT LOCF at Week 56) *p<0.0001 vs placebo; ‡p<0.002 vs. low/mid dose Placebo Qsymia Top * * * ‡ * ‡ * * ‡ * * ‡ FDA efficacy threshold Patients with > 5% Weight Loss Weight Loss, % EQUIP CONQUER EQUIP CONQUER 26
Slide 25: Pivotal 1-Year Studies: Weight Loss Over Time
* *‡ Pivotal 1-Year Studies: Weight Loss Over Time (Observed Data) * *‡ 56 ITT-LOCF Qsymia Top Qsymia Mid Qsymia Low Placebo 56 ITT-LOCF EQUIP CONQUER Time (Week) Time (Week) All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or Low 27
Slide 26: Pivotal Studies Published in Top Tier Journals
Pivotal Studies Published in Top Tier Journals 28 Lancet Obesity American Journal of Clinical Nutrition
Slide 27: Healthcare Provider Strategies at Launch
Healthcare Provider Strategies at Launch Generate awareness of Qsymia Convert currently written weight loss prescriptions (in appropriate patients) with specialists Educate PCPs on the importance of treating obesity Provide tools to providers to help counsel and engineer successful new starts 29
Slide 28: Healthcare Provider Marketing Launch Tactics
Healthcare Provider Marketing Launch Tactics Direct Mail Announcement Letter – Physicians and Medical Societies Journal Advertising Now Approved Branded Launch Ad – Upon Product Availability Digital Marketing Qsymia Website Qsymia Webcasts Medical Site Promotion Qsymia Video Education Downloadable P
Slide 29: Patient Strategies at Launch
Patient Strategies at Launch Create awareness of the approval of new and effective prescription product for obesity Elevate health risks of obesity beyond cosmetic treatment Facilitate meaningful discussions with HCP Engineer patient success and compliance with tools and support 31
Slide 30: Patient Marketing Tactics at Launch
Patient Marketing Tactics at Launch Public Relations Obesity Epidemic and Co-morbidities Qsymia availability Qsymia Patient Support Program Support Program Website Educational Tips – Email Progress Tracking Downloadable Applications Educational Video Segments Patient Database Digital Marketing Qsymi
Slide 31: Marketing, Market Access and Medical Talent Acquisition
Marketing, Market Access and Medical Talent Acquisition In last six months, 50 new hires into Commercial and Medical Affairs 33 Amgen Amylin Bristol-Myers Squibb Daiichi-Sankyo Dendreon Elan Gilead GlaxoSmithKline lpsen Johnson & Johnson Lilly Merck Novartis Novo Nordisk Roche Genentech Sanofi Taked
Slide 32: Prescriber Target Identification for Launch
Prescriber Target Identification for Launch Source: IMS Health, 2012 34
Slide 33: 25K Targets by Specialty and Prioritization
25K Targets by Specialty and Prioritization Targeting scheme prioritizes for current volume and opportunity, early adopters and affiliation efficiencies 35
Slide 34: Sales Force Deployment
Sales Force Deployment Sales Management Team are VIVUS employees National Sales Director 2 Regional Sales Directors Director, Sales Training Director, Sale Operations 16 District Managers 150 Territory Representatives PDI Partnership Recruited PCP Sales Reps with Cardio-Metabolic Experience in those
Slide 35: Insurance Coverage of Drugs to Treat Obesity Not Widely Available
Unlike Bariatric Surgery, Insurance Coverage of Drugs to Treat Obesity is Not Widely Available at Present Medicare Part D Pharmacological agents used for weight loss are an excluded category, even if used for a non-cosmetic purpose (i.e., severe obesity) Medicaid States have the option of providing
Slide 36: Future Coverage Potential
Future Coverage Potential Commercial Payers: “On the cusp of addressing a policy change” Payer’s indicate that Qsymia’s approval will push Plans/PBMs to consider formulary placement, most predicted a policy decision within 6 – 12 months Employers: “Already addressing obesity and wellness in the work
Slide 37: Key Payer/Employer Launch Activities
Key Payer/Employer Launch Activities Qsymia approval notifications being sent to Plan/PBM Medical Directors and Pharmacy Directors, Business Health Coalition Executive Directors, and State Medicaid Directors AMCP Dossier will be available to fulfill unsolicited payer requests by mid-August Seasoned
Slide 38: Qsymia Certified Home Delivery Pharmacy Network
Qsymia Certified Home Delivery Pharmacy Network In final stages of contracting with large, nationally known Mail Order and PBM pharmacies CVS Express Scripts Kaiser Walgreens Walmart Names as presented at the February FDA Advisory Committee 40
Slide 39: Significant Barriers to Off-label Generic Prescribing
Significant Barriers to Off-label Generic Prescribing FDA approved REMS and category X label Primary research with specialists and PCPs indicated this strongly discourages off-label prescribing of generics Concerns for liability Quantitative research indicates generic phentermine Rx’ing (with and wi
Slide 40: Commercial Timeline
Commercial Timeline KOL Identification and Advocacy Development PIII Publication Planning Government Relations Strategy Development Market Assessment Current Landscape and Potential Barriers Define key customer groups Initial Product Perceptions Pharmacoeconomic Planning Brand Development Core Value
Slide 41: Vivus: A Pharmaceutical Company
Vivus A Pharmaceutical Company